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Background: Long QT syndrome (LQTS) is characterized by the prolongation of QT interval, which results in 
syncope and sudden cardiac death in young people. KCNQ1 is the most common gene responsible for this 
syndrome. Methods: Molecular investigation was performed by DNA Sanger sequencing in Iranian families with a 
history of syncope. In silico examinations were performed for predicting the pathogenicity of the novel variant. 
Results: A novel homozygous KCNQ1 frameshift mutation, c.1426_1429delATGC (M476Pfs*4), was identified, and 
then the current literatures of five patients were reviewed regarding the LQTS. Conclusion: The novel frameshift 
mutation has been reported for the first time among the Iranian population. Our finding along with the case 
series study of LQTS patients illustrates the importance of genetic and case series in precise detection of the 
frequency of LQTS carriers. DOI: 10.29252/ibj.23.3.228 
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ong-QT syndrome (LQTS) is characterized by 
prolonged QT interval on the electro-
cardiograms (ECG), syncope, and cardiac 
arrest
[1,2]
. It has been reported that mutations in 16 
genes can result in inherited LQTS
[3]
. There are two 
main types of inherited LQTS: the autosomal dominant 
termed Romano-Ward syndrome (RWS) and the 
autosomal recessive type with less recurrence defined 
as Jervell-Lange Nielsen Syndrome (JLNS)
[3]
. 
Mutations in KCNQ1 gene may create both the RWS 
and JLNS disorders.  
JLNS is a condition in which QTc prolongation 
accompanying with congenital two-sided deafness 
occurs due to compound heterozygous or homozygous 
mutations in KCNQ1 and/or KCNE1 genes
[4]
. RWS is 
recognized as the aggregation of symptoms such as 
syncopal attacks and QT interval alteration in ECG 
without congenital deafness
[5]
. Although RWS is 
mostly inherited in an autosomal dominant pattern
[6]
, 
autosomal recessive inheritance is associated with 
homozygosity
[7]
. In addition, the association of JLNS 
with compound heterozygosity
[8]
 has been observed in 
some cases; the fact indicates that the pattern of 
inheritance for this disease could be more intricate.  
In this study, we present a novel homozygous 
frameshift mutation of KCNQ1 gene and review recent 
literatures on novel frameshift and recessive KCNQ1 
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MATERIALS AND METHODS 
 
Clinical evaluation 
Six unrelated LQTS patients (patients A-F) were 
referred to Emergency Department of Rajaie 
Cardiovascular, Medical and Research Center (Tehran, 




Informed consent and the study approval by the 
Ethics Committee of Pasteur Institute of Iran and 
Rajaie Cardiovascular, Medical and Research Center 
(adopted from the 1975 Helsinki Declaration) were 
obtained. Blood samples along with the ECG were 
collected from the patient and family members. Using 
the standard salting-out protocol, genomic DNA was 
extracted from the peripheral blood samples. Primer 
design was performed by Gene Runner and Primer3 
online software for coding exons and exon-intron 
boundaries and also untranslated regions of KCNQ1 
(NM_000218). Primers for KCNH2 (NM_000238) and 
SCN5A (NM_198056.2) were designed as well (Table 
1). By PCR, exons of the genes were amplified, and by 
Sanger sequencing technique, the amplicons were 
sequenced. Sanger sequencing results were compared 
with the RefSeq genomic accession numbers, and the 
variants were evaluated by Mutation Database. For 



















Patient A was a five-year-old girl with a history of 
syncope and seizure disorders. She was offspring of a 
consanguineous marriage and suffered from congenital 
sensorineural deafness. She had experienced fainting 
around the age of 2.5. There was no family history of 
convulsions, but a sudden cardiac death happened in 
proband’s sibling at six months of age (4:2 in Fig. 1). 
One stillbirth was reported by her mother in the 
previous pregnancy. Her first ECG demonstrated 
normal sinus rhythm with the prolonged QT interval of 
over 500 miliseconds (ms), as depicted in Figure. 2, 
while her parents showed normal ECG.  
Data of Sanger sequencing demonstrated a novel 
homozygous frameshift mutation, c.1426_1429 
delATGC (M476Pfs*4; ClinVar accession number: 
SCV000678249.1), in the KCNQ1 gene (Fig. 1A). The 
mutation was confirmed in the father of proband in 
heterozygous form, but the DNA sample of her mother 
was not available. The variant was considered as a 
frameshift mutation according to MutationTaster 
software. All the aforementioned predictive tools 
predicted it as a damaging and disease-causing  variant.  
 
 
    Table 1. Primers of KCNQ1, KCNH2, and SCN5A genes for coding regions 
Gene/exon  Primer sequence     Gene/exon Primer sequence 
KCNQ1 /1 F: AGCGGGATAGATGACACGAG  
R: CTTCCTGAGAGCTGGTGTGG  
 
SCN5A /2 
F:  CCTCTCTGCAAATGGTGTCC 
R: GGAAATGAGTCACTGGTGATCT 






F:  CTGACCTGCCAAATGTGCTG 
R: CCTAAGACAAATGCATGGTCAT 






F:  TGCCTATTAGGTGTCATGGAG  
R: CTTCTGGCATTAATTTGAGTTG  
     
KCNQ1 /4 
F: GTCTCTCCGTTTAGATGCTGC  
R: GGAATCTGGAGGTACCTGGC  
 
SCN5A /5 
F:  TCGTTAGCCAGATGTTTAGAGC  
R: CAGTCCACATGCAGCTCTGC 
     
KCNQ1 /5 
F: CTGTCGGGATGGACATATACC 
R: CCACACTAGGACAGCTTGAGAT  
 
SCN5A /6 
F:  TCAGTTATCCCAGGTAAGATGC  
R: GGCTATTGGCAGTGGACATG 
     
KCNQ1 /6 




F:  GAAATCAGGACAGAATCTCAGC  
R: AGGACAGACGGGTAGCAGAC 
     
KCNQ1 /7 
F: TTACATGTGCTGGTGGGACA 
R: CTGGAGTATAGCACCTTCTAGAAG  
 
SCN5A /8 
F:  TCCCGTGTCTTCTGAGAGCA  
R: GCACAGAGGAGACAGCTTCT 
     
KCNQ1 /8 
F: CTTCCAGCACTGACCATACCT 
R: GCATTGGAGCCTGTCTTCCTC  
 
SCN5A /9 
F:  ACAGCACGAACAAAGTCACG  
R: AGGATGCTCTCTGCTCTGTGA  
     
KCNQ1 /9 
F: CCACCTTTGCAAGTCTCTCC  
R: CGATGCTAGGTTCCTGCCATC  
 
SCN5A /10 
F:  CTCTGCAGGTCAGTACATGTCC 
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Gene/exon  Primer sequence    Gene/exon Primer sequence 
KCNQ1 /10 
F: CTGTGTGAAGACACTGGAGCTG  
R: GGTCTCTGACAACGAGGTATGAA  
 
SCN5A /11 
F:  CTGTCTGAGTTTATCTCCATGATG  
R: CCATAAGAGTGAGGGTCCATT 
     
KCNQ1 /11 
 
F: TGATTGTCAGTGCTGGAGCT  
R: GTGCTATCTACTCGCCTAGTGC  
 
SCN5A /12 
F:  CAAGCCCAGTTAAGTTTCAGG  
R: CTCTAGGTGCATAAACTTACA  






F:  TGTCCCATCAAGACCTTCATC 
R: CTGTTCTGTGTAGCCTTGCC  
     
KCNQ1 /13 
F: CGGTGAGTAGACAGGAAGCTG 
R: GAGTTCTTGCCTCTCAACCAC  
 
SCN5A /14 
F:  TGTCCTGATAATCTCTCCTGTCC 
R: GCTGAGAAATGTAGATTTGGAGT  
     
KCNQ1 /14 
F: AACTAGCTCCGTGTGTTACAGG  
R: TGCATGACATGAAATGAAAGC  
 
SCN5A /15 
F:  TGCCTGGTATGCTTGGTGAG  
5´-GTCATGCCTTCACCCAACAG  
     
KCNQ1 /15 
F: TCAGAGGTGGAGAGCGTGGA  
R: CGTAGTCTGCTTTGTGCTCTG  
 
SCN5A /16 
F:  GAAACAGTAGTGGGTGCTCTGG  
R: CACCAATGAACACACCAATCTAT  
     
KCNQ1 /16 
F: AGACATAGGGTGCACACGTG 
R: CGTCTCAGGTCTGAGTTGTTAC  
 
SCN5A /17 
F:  AAGCCTCGGAGCTGTTTGTC  
R: CTCCCTTCCTAACTCAGTCCAG  




R: GGAAACTCAGCTCAGGCTTTTGG  
 
SCN5A /18 
F:  GAGGAGTCTTCAGTGAGATGGAG 
R: CTCTGATGCAGGACTAACCCA 







F:  AGCCTTAGACTCCAGCAGACC 
R: TCCATCTGCCTGACGTGTCT  







F:  CCATCCTCCTCAAAGAGTGC  
R: GGAACAGCTCACAAACTCTCAA 
    
KCNH2 /4 
 




F:  CTCATCTAGTTCCTGTTTCTGCT  
R: CGTAAGTCTGAGTGACCCAGG 
    
KCNH2 /5 
 
F: TGGCTGCTTCCTTAGAGTGG  
R: GCAATCTATTCCAGAGCTGC  
 
SCN5A /22 
F:  CCAGAAGCCAGGATACTCTTG  
R: AGGCTAGGCAGCTGTGAGAA  




R: CCTATGCTCCTTCTCTCCACA  
 SCN5A /23 F:  GGAAACCAGATGTTCTGAAGC 
R: CAGTTCTAGAACCGATACCATGT  
    
KCNH2 /7 
 
F: AGGAGGAGGGTCTAGGAAGTC  
R: TCGACGCTGAGACTGAGACA 
 SCN5A /24 F:  CTGACCACCCAGGCATTTAG  
R: GTCACTCTGGAGTTCAGCCTC 
    
KCNH2 /8 
 
F: TGGAGCGCAGATGTACAAGG  
R: CACAGTCAGTAGTAAGGACCCTG  
 
SCN5A /25 
F:  TAGTGACCTTCCTCTAGATACACC  
R: CCTGTAAGAACGTAAGAAGGG 
    
KCNH2 /9 
 
F: CTGATGCTTCCGAGATCTCC  
R: GAGGAAGAAATGCTAGCCTGG  
 
SCN5A /26 
F:  GGTGGATACTGGATTTGCAG   
R: AGGTATGATAAGGATGTAGCATC 
    
KCNH2 /10 
 




F:  GGACAGCCAGTGGCTTTAGC  
R: CTGAATGCCATGTACAACCCT  







F:  GCTCCTTGCCATATAGAGACC  
R: CATCGTGGTCAACATGTACATT  
    
KCNH2 /12,13 
 
F: CAAGATAGCAGAAGAAGCGAC  
R: AGCTGGATCCCCTTCTTCCA   
 
SCN5A /28.2 
F:  GACATGTTCAACTTCCAGACCT  
R: GGTTATCCAGAGAGCCTTCC  
    
KCNH2 /14 
 
F: GGTGTTGTCTGGTAGAGGGAG  
R: GTGGTCTCCAAGAACTGACTGA  
 
SCN5A /28.3 
F:  CCCAACCAGATAAGCCTCAT  
R: GGAGTAAGAAATGGGCCTCA  
    
KCNH2 /15 
F: GCTCCTGCTCTCAGAGAATGC 
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Fig 1. Pedigree and mutation confirmation. (A) Family pedigree for the patient A; (B) DNA Sanger sequencing confirmation of 
c.1426_1429delATGC (M476Pfs*4) mutation (arrows) in the index case with homozygote condition (middle), unaffected 
heterozygote father (lower), and a normal control sequence (upper). 
 
 
This mutation introduces three novel amino acids after 




Fig 2. The electrocardiogram (ECG) of the index case. The 
12-lead ECG of the patient A at five years of age (QTc over 500 
ms in lead II; heart rate, 72 beat/min; with a paper speed of 25 
mm/s and 10 mm/mV at 20 Hz). 
acid, was changed to proline) and premature stop 
codon at 480 that resulted in a truncated protein. 
Patients  B  and C  were  referred  to  the  clinic  due  
to syncope and a prolonged QTs interval of >600 and 
560 ms,  respectively.  Except for hearing defect, 
physical and neurological examinations were totally 
normal, and also there was no electrolyte imbalance. 
Sanger sequencing of the KCNQ1 gene for both cases 
showed a homozygous frameshift mutation, 
c.733_734delGG (p.G245Rfs*39), in the exon 5. This 
frameshift results in a premature stop codon and 
develops a truncated protein. Examination of the 
parents of two patients showed heterozygosity for this 
mutation. In our previous study
[15]
, using STR markers, 
we demonstrated this frameshift mutation in two 
obviously unrelated families with the same origin, 
which may represent a founding effect. 
Patients D and E were presented by the recurrent 
episodes of syncope and a prolonged QTs interval of 
>550 and 600 ms, respectively. Analysis of the DNA 
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mutation of c.1691A>G in the KCNQ1 gene. The same 
mutation was also identified in patient E by next-
generation sequencing. This variant has not previously 
been reported in Exome Aggregation Consortium 
(ExAC) or 1000 Genome databases. Co-segregation 
analysis confirmed the association of LQTS with the 
mentioned variant, and a same haplotype was detected 
in the two families. Using in silico analysis, we 
identified the p.D564G variant as a deleterious  
variant. 
Patient F had a background of recurrent syncope, 
which the first episode occurred at the age of 18 
months. Resting 12-lead ECG showed noticeably a 
prolonged QTc interval of >580 ms. Echocardiography 
detected a structurally normal heart, and the ECG of 
her parents was normal. Sanger sequencing of the 
KCNQ1 gene exhibited a homozygous mutation, 
c.1532_1534delG (p. A512Pfs*81), that led to a 
premature stop codon. Her parents were heterozygous 
for this mutation. This variant has not been reported in 





In the present research, the mutation analysis of the 
KCNQ1, KCNH2, and SCN5A genes were performed in 
a patient among a cohort of 30 unrelated Iranian LQTS 
families. The sequence analysis of the index patient 
demonstrated the absence of mutation in the SCN5A 
and KCNH2 genes but showed a novel homozygous 
mutation, c.1426_1429delATGC (M476Pfs*4), in 
KCNQ1 gene. Five patients screened previously were 
found to have a missense mutation in two RWS 
families
[16]




The novel mutation was detected neither in ExAC 
nor in 1000 Genome; additionally, it has not been 
reported in any disease database such as HGMD and 
LOVD. In the index case, the 4-bp deletion was  
located at positions 1426 to 1429 in exon 11 of 
KCNQ1 gene, which led to amino acid sequence 
alteration and was accordingly considered as a 
frameshift variant. 
It has been shown that frameshift mutations leading 
to truncated proteins are responsible for the majority of 
JLNS cases
[19,20]
. Wei et al.
[21]
 have reported a one-
nucleotide deletion in the position 1188 of KCNQ1 
gene, which causes a frameshift and leads to a 
premature stop codon and consequently, results in a 
259-amino-acid deletion in the C-terminal. Another 
study has demonstrated that a frameshift may lead to 
the loss of function of the potassium channel, due to a 
single nucleotide insertion onto the position 1149 of 
this gene
[22]
. In LQTS patients, frameshift mutation has 
been predicted to be a pathogenic mutation with an 
estimated predicted value of 99%
[23]
. In concordance 
with the genetic study result, our patient showed the 
clinical features of seizure, recurrent episodes of 
syncope, and the family history of serious heart events 
such as sudden cardiac death in the sibling of the 
proband who died at six months of age (4:2 in Fig. 1). 
Likewise, a congenital sensorineural deafness was 
observed in the proband in agreement with most 
previous reports in JLNS patients
[24,25]
. 
The probands B, C, and F were categorized as 
patients of JLNS, the recessive form of LQTS. A 
frameshift mutation (p. A512Pfs*81) was found in 
patient F. In B and C non-consanguineous families, the 
frameshift mutation, c.733_734delGG, happened in the 
C-loop between the transmembrane domains S4-S5 of 
the protein. The C-loop domains have a significant role 
in changing the potassium channel’s function; 
therefore, mutations in the residues of this region may 
impair the voltage-dependent activation of the channel, 
hence leading  to increased risk of lethal cardiac 
events
[26]
. Functional assay showed that mutations in 
the C-loop of KCNQ1 gene impress the adrenergic 
regulation of channel, either in the absence or in the 
presence of wild-type subunits
[27,28]
.  
To confirm whether the novel missense variant of 
c.1691A>G (p.D564G) in cases D and E is pathogenic, 
further analysis was conducted. In silico investigations 
by the predictive software indicated that the 
substitution of aspartic acid with glycine at codon 564 
may be a disease-causing mutation. SIFT, Polyphen-2, 
MutationTaster, and FATHMM classified the p.A564G 
as a damaging variant. The conservation scores 
predicted by Phylop, PhastCons, and GERP++ were 
4.32, 1, and 4.02, respectively. These analyses also 
revealed that aspartic acid 564 is located in the C-
terminal domain of KCNQ1 channel, in a highly 
conserved α-helix region. In addition, Mutation 
Mapper showed the aspartic acid at position 564 was 
conserved among 100 different species. Consequently, 
according to the American College of Medical 
Genetics and Genomics guidelines (ACMG), the 




This is the first report of a novel homozygous 
frameshift mutation with JLNS.  Based on ACMG, this 
mutation is likely to abolish channel function, severely. 
Identification of six JLNS and RWS index cases in a 
period of 24 months in a cardiogenetic clinic in Tehran 
suggests the high prevalence of LQTS. This high 
prevalence necessitates a broader surveillance in the 
country and reveals the importance of genetic and case 
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